BAGSVAERD, DENMARK--(Marketwire - July 13, 2009) - On 29 January 2009, Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.
Since the announcement as of 6 July 2009, the following transactions have been made under the programme:
Number of Average Transaction shares purchase price value, DKK Accumulated, last announcement 8,759,682 2,429,210,357 6 July 2009 75,000 289.3600 21,702,000 7 July 2009 75,000 291.0200 21,826,500 8 July 2009 75,000 292.3400 21,925,500 9 July 2009 80,000 289.5900 23,167,200 10 July 2009 75,000 284.9800 21,373,500 Accumulated under the programme 9,139,682 2,539,205,057
With the transactions stated above, Novo Nordisk owns a total of 19,931,741 treasury shares, corresponding to 3.2% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
Company Announcement no 42 / 2009
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
Further information:
Media:
Outside North America:
Elin K Hansen
Tel: (+45) 4442 3450
Email Contact
In North America:
Sean Clements
Tel: (+1) 609 514 8316
Email Contact
Investors:
Outside North America:
Mads Veggerby Lausten
Tel: (+45) 4443 7919
Email Contact
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
Email Contact
In North America:
Hans Rommer
Tel: (+1) 609 919 7937
Email Contact